(Q40787014)

English

A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

23 September 2017

A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant (English)

1 reference

Europe PubMed Central

23 September 2017

toll-like receptor

0 references

5

1 reference

Europe PubMed Central

23 September 2017

Tonya Villafana

10

object named as

Tonya Villafana

1 reference

Europe PubMed Central

23 September 2017

author name string

Judith Falloon

1

1 reference

Europe PubMed Central

23 September 2017

Fei Ji

2

1 reference

Europe PubMed Central

23 September 2017

Craig Curtis

3

1 reference

Europe PubMed Central

23 September 2017

Stephan Bart

4

1 reference

Europe PubMed Central

23 September 2017

Diane Krieger

6

1 reference

Europe PubMed Central

23 September 2017

Filip Dubovsky

7

1 reference

Europe PubMed Central

23 September 2017

Stacie Lambert

8

1 reference

Europe PubMed Central

23 September 2017

Therese Takas

9

1 reference

Europe PubMed Central

23 September 2017

Mark T Esser

11

1 reference

Europe PubMed Central

23 September 2017

language of work or name

0 references

publication date

19 April 2016

1 reference

Europe PubMed Central

23 September 2017

1 reference

Europe PubMed Central

23 September 2017

34

1 reference

Europe PubMed Central

23 September 2017

25

1 reference

Europe PubMed Central

23 September 2017

2847-2854

1 reference

Europe PubMed Central

23 September 2017

Respiratory syncytial virus infection in elderly and high-risk adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.002

7 January 2021

Respiratory syncytial virus- and human metapneumovirus-associated emergency department and hospital burden in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.002

7 January 2021

Is clinical recognition of respiratory syncytial virus infection in hospitalized elderly and high-risk adults possible?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.002

7 January 2021

Latitudinal variations in seasonal activity of influenza and respiratory syncytial virus (RSV): a global comparative review

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.002

7 January 2021

Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illness

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.002

7 January 2021

Mortality caused by influenza and respiratory syncytial virus by age group in England and Wales 1999-2010.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.002

7 January 2021

High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.002

7 January 2021

Modelling estimates of the burden of Respiratory Syncytial virus infection in adults and the elderly in the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.002

7 January 2021

Serum antibody decay in adults following natural respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.002

7 January 2021

Immunity to and frequency of reinfection with respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.002

7 January 2021

The cost-effectiveness of a hypothetical respiratory syncytial virus vaccine in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.002

7 January 2021

RSV vaccine in development: assessing the potential cost-effectiveness in the Dutch elderly population.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.002

7 January 2021

Role of influenza and other respiratory viruses in admissions of adults to Canadian hospitals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.002

7 January 2021

Risk factors for severe respiratory syncytial virus infection in elderly persons

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.002

7 January 2021

Adults 65 years old and older have reduced numbers of functional memory T cells to respiratory syncytial virus fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.002

7 January 2021

Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.002

7 January 2021

Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.002

7 January 2021

Molecular and cellular response profiles induced by the TLR4 agonist-based adjuvant Glucopyranosyl Lipid A

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.002

7 January 2021

A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.002

7 January 2021

Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.002

7 January 2021

Enhanced immunogenicity of a respiratory syncytial virus (RSV) F subunit vaccine formulated with the adjuvant GLA-SE in cynomolgus macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.002

7 January 2021

Enzyme-linked immunospot assay for detection of human respiratory syncytial virus f protein-specific gamma interferon-producing T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.002

7 January 2021

Cell-mediated immune responses to respiratory syncytial virus infection: magnitude, kinetics, and correlates with morbidity and age

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.002

7 January 2021

CD8+ T cell immunity against human respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.002

7 January 2021

Identifiers

10.1016/J.VACCINE.2016.04.002

1 reference

Europe PubMed Central

23 September 2017

release_ceqgbzomgjdyxbbynkuimnkaiu

1 reference

https://api.fatcat.wiki/v0/release/ceqgbzomgjdyxbbynkuimnkaiu

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

23 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40787014&oldid=1907365197"